Wells Fargo’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-332,492
| Closed | -$59.8M | – | 6759 |
|
|
2017
Q3 | $59.8M | Buy |
332,492
+249,262
| +299% | +$34.7M | 0.02% | 782 |
|
|
2017
Q2 | $8.63M | Buy |
83,230
+34,581
| +71% | +$2.82M | ﹤0.01% | 2024 |
|
|
2017
Q1 | $3.82M | Sell |
48,649
-17,832
| -27% | -$1.1M | ﹤0.01% | 2660 |
|
|
2016
Q4 | $2.98M | Buy |
66,481
+38,809
| +140% | +$1.9M | ﹤0.01% | 2838 |
|
|
2016
Q3 | $1.55M | Sell |
27,672
-998
| -3% | -$55.6K | ﹤0.01% | 3170 |
|
|
2016
Q2 | $1.43M | Sell |
28,670
-536
| -2% | -$26.3K | ﹤0.01% | 3212 |
|
|
2016
Q1 | $1.34M | Buy |
29,206
+4,533
| +18% | +$220K | ﹤0.01% | 3208 |
|
|
2015
Q4 | $1.52M | Sell |
24,673
-4,168
| -14% | -$293K | ﹤0.01% | 3193 |
|
|
2015
Q3 | $1.61M | Buy |
28,841
+5,281
| +22% | +$332K | ﹤0.01% | 3158 |
|
|
2015
Q2 | $1.44M | Buy |
23,560
+6,702
| +40% | +$382K | ﹤0.01% | 3323 |
|
|
2015
Q1 | $973K | Buy |
16,858
+11,058
| +191% | +$741K | ﹤0.01% | 3555 |
|
|
2014
Q4 | $334K | Sell |
5,800
-700
| -11% | -$29.5K | ﹤0.01% | 4162 |
|
|
2014
Q3 | $185K | Buy |
+6,500
| New | +$161K | ﹤0.01% | 4384 |
|
Wells Fargo's KITE Position: Q4 2017 in Review
Wells Fargo sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 332,492 shares — an estimated $59.8M sold.
Wells Fargo first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $59.8M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Wells Fargo reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Wells Fargo sold 332,492 Kite Pharma, Inc. shares in Q4 2017, an estimated $59.8M.
- Wells Fargo first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Wells Fargo's Kite Pharma, Inc. position peaked at $59.8M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Wells Fargo's 13F filing for Q4 2017, filed 8 Feb 2018.